ASMB
HEALTHCAREAssembly Biosciences Inc
$31.36+1.81 (+6.13%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving ASMB Today?
No stock-specific AI insight has been generated for ASMB yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$11.64$39.71
$31.36
Fundamentals
Market Cap$498M
P/E Ratio—
EPS$-0.55
Dividend Yield—
Dividend / Share—
ROE-0.1%
Profit Margin-0.1%
Debt / Equity—
Trading
Volume156K
Avg Volume (10D)—
Shares Outstanding15.9M
ASMB News
22 articles- Assembly Biosciences Q1 revenue falls, net loss widensTradingView·May 8, 2026
- Assembly Biosciences: Q1 Earnings SnapshotKVUE·May 7, 2026
- Assembly Biosciences (ASMB) Reports Q1 Loss, Misses Revenue EstimatesYahoo Finance·May 7, 2026
- Assembly Biosciences Reports First Quarter 2026 Financial Results and Recent HighlightsYahoo Finance·May 7, 2026
- Assembly Biosciences Highlights Presentations on Positive Phase 1b Data for ABI-5366 and ABI-1179 in Recurrent Genital Herpes at ESCMID Global 2026Yahoo Finance·Apr 9, 2026
- Assembly Biosciences (ASMB) Q4 Earnings and Revenues Top EstimatesYahoo Finance·Mar 19, 2026
- Assembly Biosciences: Q4 Earnings SnapshotYahoo Finance·Mar 19, 2026
- Assembly Biosciences Reports Year-End 2025 Financial Results and Recent HighlightsYahoo Finance·Mar 19, 2026
- Metagenomi Therapeutics (MGX) Reports Q4 Loss, Misses Revenue EstimatesYahoo Finance·Mar 5, 2026
- Personalis (PSNL) Reports Q4 Loss, Misses Revenue EstimatesYahoo Finance·Feb 26, 2026
- Supernus Pharmaceuticals (SUPN) Surpasses Q4 Earnings and Revenue EstimatesYahoo Finance·Feb 25, 2026
- With 32% ownership, Assembly Biosciences, Inc. (NASDAQ:ASMB) has piqued the interest of institutional investorsYahoo Finance·Dec 24, 2025
- GILD Exercises Option to License Assembly Bio's Herpes ProgramsYahoo Finance·Dec 23, 2025
- Gilead Sciences Exercises Option to License Assembly Biosciences’ Helicase-Primase Inhibitor Programs for Recurrent Genital HerpesYahoo Finance·Dec 22, 2025
- Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing Reductions in Viral Shedding Rate and Virologically Confirmed Genital Lesion Rate in Recurrent Genital HerpesYahoo Finance·Dec 8, 2025
- Assembly Biosciences, Inc.'s (NASDAQ:ASMB) Shift From Loss To ProfitYahoo Finance·Dec 3, 2025
- Here's Why We're Not At All Concerned With Assembly Biosciences' (NASDAQ:ASMB) Cash Burn SituationYahoo Finance·Nov 13, 2025
- Assembly Biosciences: Q3 Earnings SnapshotYahoo Finance·Nov 10, 2025
- Assembly Biosciences Reports Third Quarter 2025 Financial Results and Recent UpdatesYahoo Finance·Nov 10, 2025
- US Live Biotherapeutics Market Research 2025, Competitive Analysis of Arrant Bio, 4D Pharma, Cerbios, Biose, Assembly Biosciences, Wacker Chemie, Quay Pharmaceuticals, NIZO, Lonza, Inpac ProbioticsYahoo Finance·Nov 10, 2025
- Assembly Biosciences Presents Positive Phase 1b Data for Next-Generation Capsid Assembly Modulator ABI-4334 at AASLD The Liver Meeting®Yahoo Finance·Nov 7, 2025
- Supernus Pharmaceuticals (SUPN) Surpasses Q3 Earnings and Revenue EstimatesYahoo Finance·Nov 4, 2025
All 22 articles loaded
Price Data
Open$27.83
Previous Close$29.55
Day High$29.78
Day Low$27.83
52 Week High$39.71
52 Week Low$11.64
52-Week Range
$11.64$39.71
$31.36
Fundamentals
Market Cap$498M
P/E Ratio—
EPS$-0.55
Dividend Yield—
Dividend / Share—
ROE-0.1%
Profit Margin-0.1%
Debt / Equity—
Trading
Volume156K
Avg Volume (10D)—
Shares Outstanding15.9M
About Assembly Biosciences Inc
Assembly Biosciences, Inc. is a clinical-stage biotechnology company in the United States. The company is headquartered in South San Francisco, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—